Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, by Disease Type (Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, and Others), by Drug Class (Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Feb 2022

Code : CMI4920

Pages :211

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Restraint

High cost of treatment for chronic liver diseases is a major factor, which is expected to hinder the market growth. Furthermore, owing to this factor, a large patient pool suffering from CLD is unable to avail proper treatment. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others, which are overpriced for the patients in low and middle income countries in the (Middle East and North Africa) MENA region. For instance, the cost of surgical treatment of liver cancer in Herzliya Medical Center, Israel, is US$ 25,000 and the cost of chemotherapy starts at US$ 3,500.

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 263,563,622 cases and 5,232,562 deaths due to coronavirus disease (COVID-19) were reported till December 03, 2021, across the globe.

Treatment options for cancer such as chemotherapy can weaken the immune system of cancer patients and increase the risk of getting infected. Hence, people suffering from cancer such as liver cancer are at higher risk of developing serious complications due to COVID-19 infection.

Moreover, healthcare providers are adopting telehealth solutions to conduct their services for patients with severe chronic liver disease while maintaining social distancing to combat COVID-19 pandemic without compromising the health of patients with chronic liver disease. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking above mentioned measures to reduce the spread of COVID-19 infection.

Furthermore some studies also indicated that, COVID-19 was significantly associated with alcoholic liver damage. Nevertheless, impact of alcohol during COVID-19 within the alcohol consumption and ALD may impact COVID-19 pathogenesis.